{
  "ticker": "CGF",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976716",
  "id": "02976716",
  "pages": 39,
  "price_sensitive": false,
  "date": "20250804",
  "time": "1718",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mj6pfk4jmz5s.pdf",
  "summary": "**Material Information Summary:**\n\n1. **Type of Announcement:** *Ceasing to be a Substantial Holder* (Form 605 filing).  \n   - **Entity Involved:** MS&AD Insurance Group Holdings, Inc. has ceased to be a substantial holder in **Challenger Limited (ASX: CGF)**.  \n\n2. **Transaction Context:**  \n   - A **Sale and Purchase Agreement** dated **4 April 2025** was executed between MS&AD (Seller) and TAL Dai-ichi Life Australia Pty Ltd (Buyer).  \n   - **Sale Shares:** 104,353,125 ordinary shares (or 103,709,353 if scaled back per conditions).  \n   - **Purchase Price:** JPY 766.627736352 per share (total ~JPY 80 billion, ~AUD 765 million at JPY 1:AUD 0.00955).  \n   - **Conditions Precedent:** FIRB, APRA, and UK FCA approvals.  \n\n3. **Key Dates:**  \n   - **End Date:** 4 May 2026 (for conditions to be met).  \n   - **Completion Timing:** 15\u201325 business days post-condition satisfaction (or scale-back/rejection notice).  \n\n4. **Material Clauses:**  \n   - **Price Adjustments:** Purchase price may increase if Buyer acquires additional shares at a higher price pre-Completion.  \n   - **Residual Shares (if APRA approval fails):** Seller may sell 643,772 residual shares to third parties, with Buyer covering any shortfall vs. Initial Price.  \n\n5. **Regulatory:**  \n   - FIRB, APRA (for SIS Act compliance), and UK FCA approvals required.  \n   - Rejection of APRA approval triggers scale-back (clause 3.8).  \n\n6. **Liquidity Impact:**  \n   - Large block trade (~15% of CGF\u2019s issued shares) likely to affect market liquidity.  \n\n**Excluded:** Legal boilerplate, jurisdictional details, and non-material operational clauses.  \n\n**Conciseness Note:** Focused on actionable trading/capital markets insights (e.g., size, price, regulatory hurdles). No speculative analysis added.",
  "usage": {
    "prompt_tokens": 18085,
    "completion_tokens": 462,
    "total_tokens": 18547,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T08:03:52.344992"
}